Siemens Vision 600 PET/CT scanner or equivalent
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation RFP-NIH-OD-26-006312 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
Acquisition of one Siemens Vision 600 PET/CT scanner or equivalent. This procurement is urgently needed to replace an existing PET/CT scanner that will be end of service life on 31DEC2026 with a new state-of-the art PET/CT imaging system. The replacement will be used to perform clinical PET/CT scans in Clinical Center adult and pediatric patients with cancer and other serious conditions. The proposed PET/CT with state-of-the art sensitivity, resolution and field of view renders the current scanner obsolete. The resulting improved image quality allows for better detection and characterization o… (show all)
f lesions, which is essential for accurate diagnosis and treatment planning. It is a requirement and responsibility for the Clinical Center to make available state-of-the-art imaging technology supporting its innovative clinical research protocols and to replace obsolete technology. This procurement is necessary for continuity of safe and quality patient care and is directly related to human safety. There is no alternative to this obsolete PET/CT beyond 31DEC2026. Expedited procurement processing is respectfully requested. PLEASE SEE ATTACHMENT FOR DETAILS.
Who won similar work
25 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same industry group (NAICS 3345).
Single-winner award sizes (25): middle half $37K to $230K, median $65K; range $14K to $5.9M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AGILENT TECHNOLOGIES INC · $A · $6.8B | 2 | $401K | Jul 24, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 2 | $283K | Dec 17, 2025 |
| 10X GENOMICS, INC. · $TXG · $618.7M | 2 | $77K | Sep 22, 2025 |
| GE PRECISION HEALTHCARE LLC | 1 | $5.9M | Sep 17, 2025 |
| FEI COMPANY | 1 | $1.8M | Sep 22, 2025 |
| BRUKER BIOSPIN CORP · $BRKR · $3.0B | 1 | $1.4M | Sep 18, 2025 |
| BECTON, DICKINSON AND COMPANY · $BDX · $19.4B | 1 | $1.3M | Jan 3, 2025 |
| BRUKER NANO, INC · $BRKR · $3.0B | 1 | $230K | Aug 14, 2026 |
| Sony Biotechnology Inc. | 1 | $227K | Aug 17, 2026 |
| NEWPORT CORP | 1 | $212K | Jul 8, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $A reported $6.8B revenue in FY2025. The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. 10-K
- $TXG reported $618.7M revenue in FY2025. The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. 10-K
- $BRKR reported $3.0B revenue in FY2025. The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. 10-K
- $BDX reported $19.4B revenue in FY2025. The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and Analyzer
- Sep 25, 2026NIKON INSTRUMENTS INC$40K66--Warming Box/Enclosure for Nikon Eclipse Ti-2 AX co
- Aug 17, 2026Sony Biotechnology Inc.$227K66--NIMH: Purchase order for One (1) Microfluidic Base
- Aug 14, 2026BRUKER NANO, INC$230K66--NIMH: Purchase order for One (1) Miniaturized Head
- Aug 7, 2026BITTIUM USA INC.$48K66--NIMH: Non Competitive Combined Synopsis for Faros
- Jul 10, 2026BECKMAN COULTER, INC$31K66--Purchase Order for two (2) Hematology Analysers
- Jul 10, 2026AMUZA INC.$115K66--NIMH: Purchase order for four (4) wireless fiber p
- Jul 8, 2026NEWPORT CORP$212K66--RFQ for One (1) Tunable Laser Multi-Photon Microsc
- Jul 8, 2026SR RESEARCH LIMITED$37K66--NIMH: Purchase Order for One (1) EyeLink 1000 Plus
- Jul 8, 2026PARSE BIOSCIENCES, INC.$67K66--PO for One (1) Evercode WT v3 with UDI Plate and
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 4 of the past winners are listed companies
- 0 insider buys and 8 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.